

|  |               |
|--|---------------|
| MINISTERSTVO ZDRAVOTNÍCTVA SR<br>podateľňa |               |
| Došlo:                                     | - 2 -04- 2020 |
| Šv.č.zoznamu:<br>2018429                   | Č.spisu:      |
| Prilohy/listy:                             | Vybavuje:     |

Eli Lilly Slovakia, s.r.o.

Panenská 6  
811 03 Bratislava  
Slovenská republika  
+421 2 2066 3111  
www.lilly.sk

Bratislava, 1.4.2020

Ministerstvo zdravotníctva SR  
Sekcia farmácie a liekovej politiky  
Limbová 2  
83752 Bratislava

**Vec: Upovedomenie o úprave zoznamu liekov v informačnom systéme na mimoriadne objednávanie liekov –ISMOL na stránke MZ SR.**

Podľa § 60 odseku (1) a bodu ae.) Zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach a o zmene a doplnení niektorých zákonov v znení neskorších predpisov (ďalej len „**Zákon o liekoch**“), Eli Lilly Slovakia, s.r.o. **vystupoval** ako zástupca držiteľa registrácie lieku:

**Daiichi Sankyo Europe GmbH**

sídlom na adrese: Zielstattstrasse 48, Munich 81379, Nemecko

ohľadom humánných liekov uvedených v zozname nižšie (“**Lieky**”)

| ŠÚKL  | Názov lieku                         | Doplnok                       |
|-------|-------------------------------------|-------------------------------|
| 66216 | Efient 10 mg filmom obalené tablety | tbl flm 28x10 mg (blis.Al/Al) |
| 66209 | Efient 5 mg filmom obalené tablety  | tbl flm 28x5 mg (blis.Al/Al)  |

Týmto len opakovane upovedujeme Ministerstvo zdravotníctva, že informačný systém na mimoriadne objednávanie liekov (“**Systém**”) bol vytvorený a je prevádzkovaný od 1.4.2017 na webovej stránke

[www.isliek.sk](http://www.isliek.sk)

Prevádzkovaním tohto systému bola poverená spoločnosť Movianto Slovensko, s.r.o., so sídlom na adrese Ďiaľničná cesta 4431/14A, 903 01 Senec, **ale od 1.4. 2020 uz nebudú vyššie uvedené lieky súčasťou informačného systému**

V prílohe zasielame dokument o ukončení zastupovania Daiichi Sankyo Europe GmbH spoločnosťou Eli Lilly Slovakia, s.r.o.

S pozdravom,

MUDr. Dana Böhmová

konateľ Eli Lilly Slovakia, s.r.o.

**Eli Lilly Slovakia, s.r.o.**

PANENSKÁ 6  
811 03 BRATISLAVA  
tel.: 02/2066 3111, fax: 02/2066 3119  
IČO: 35 873 957, DIČ: 2021778165

V ZASTÚPENÍ *Mestkova*

## Letter of Agreement

March 6, 2020

DAIICHI SANKYO COMPANY, LIMITED  
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426, Japan  
Attn: Dr. Ohtsuki Masahiko – VP, BD & Licensing Department

RE: Letter Agreement regarding the Termination and Transition Agreement with an effective date of March 18, 2019 as applicable to the country transfer date for Czech Republic and Slovakia.

Dear Dr. Ohtsuki:

Reference is made to that certain Termination and Transition Agreement dated March 18, 2019 (the "Agreement"), by and between Eli Lilly and Company ("LILLY") and DAIICHI SANKYO COMPANY, LIMITED ("DAIICHI SANKYO") relating to the termination of a Co-Development and Licensing Agreement dated June 19, 2001, as amended including all letter agreements, memorandums of understanding or other ancillary agreements between the Parties or their respective Affiliates, and the related agreements including the Co-Marketing Agreement, the Co-Promotion Agreement, and the Exclusive License Agreement, all of which are dated June 19, 2001; the Manufacturing and Supply Agreement dated August 20, 2002; the Safety Agreement dated March 5, 2002; and the US Co-Promotion Agreement dated July 9, 2009; all as amended from time to time and all of which being collectively referred to herein as the "PRASUGREL Agreements".

The parties have agreed to certain modifications to the Termination and Transition Agreement upon the terms outlined in this Letter Agreement.

1. There has been a change in DAIICHI SANKYO'S position regarding the transition of Prasugrel business in Czech Republic and Slovakia. Originally, those countries were scheduled to be transitioned to DAIICHI SANKYO on August 31, 2020. LILLY and DAIICHI SANKYO agree to transition Prasugrel business in Czech Republic and Slovakia on March 31, 2020.
2. This Letter Agreement shall come into effect on the last signature date below (the "Effective Date") as agreed and acknowledged by the parties' duly authorized representatives and will remain in effect unless terminated by the parties.
3. A party shall not be held liable for failure of or delay in performing its obligations under this Letter Agreement if such failure or delay is the result of an act of God, such as earthquake, hurricane, tornado, flooding, or other natural disaster, or in the case of war, action of foreign enemies, terrorist activities, labor dispute or strike, government sanction, blockage, embargo, or failure of

electrical service. The non-performing party must make every reasonable attempt to minimize delay of performance.

4. All other terms and conditions of the Termination and Transition Agreement not amended shall remain in full force and effect.

Please indicate your agreement with the foregoing by executing a copy of this letter in the space provided below and returning an executed copy to the undersigned.

Very truly yours,



By: \_\_\_\_\_

Printed: Patrik Jonsson

Title: Sr. VP and President, Lilly Bio-Medicines

March 17, 2020

Agreed to and Acknowledged by:

DAIICHI SANKYO COMPANY, LIMITED

By: Masahiko Ohtsuki

Dr. Ohtsuki Masahiko – VP, BD & Licensing Department

Date: March 19, 2020